Xencor Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Xencor (XNCR) Tops Q1 EPS by 24c, Revenues Beat
May 7, 2020 4:02 PM EDTXencor (NASDAQ: XNCR) reported Q1 EPS of ($0.14), $0.24 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $32.39 million versus the consensus estimate of $15.06 million.
Xencors XmAb® technologies enable us, and our partners, to create antibodies and cytokines with enhanced properties and potential new mechanisms of therapeutic action. Today, our clinical-stage XmAb bispecific antibodies and cytokines include five wholly owned candidates, two being co-developed... More
